Multiple myeloma future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
Sergekorjian (talk | contribs) No edit summary |
(Mahshid) |
||
| Line 21: | Line 21: | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Neurology]] | |||
[[Category:Neurosurgery]] | |||
Revision as of 02:48, 27 November 2017
|
Multiple myeloma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Multiple myeloma future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Multiple myeloma future or investigational therapies |
|
Multiple myeloma future or investigational therapies in the news |
|
Blogs on Multiple myeloma future or investigational therapies |
|
Risk calculators and risk factors for Multiple myeloma future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Vidit Bhargava, M.B.B.S [2]
Overview
The lymphoma-like polychemotherapy regimen, carfilzomib, and Bruton's tyrosine kinase inhibitor CC-292 are investigational therapies for the treatment of multiple myeloma.
Future or Investigational Therapies
- Lymphoma-like polychemotherapy regimen "Dexa-BEAM" (including dexamethasone, carmustine, cytarabine, etoposide and melphalan) in treating advanced and extramedullary multiple myeloma has been studied by Rasche L etal. It showed improved survival, when used as a bridge to stem cell transplantation.[1]
- Carfilzomib is a new proteasome inhibitor that selectively and irreversibly binds to its target, resulting in sustained inhibition. It thus has a better response as compared to bortezomib along with a favorable safety profile. Clinical trials have been approved and under process to study the effects of the drug. The prospect of its combination with several other agents such as immunomodulators, alkylating agents, glucocorticoids, histone deacetylase inhibitors and kinesin spindle protein inhibitors also holds promise.[2]
- Eda etal is studying a novel Bruton's tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib and its rols as anti-multiple myeloma combiantion therpay.[3]
References
- ↑ Rasche, L.; Strifler, S.; Duell, J.; Rosenwald, A.; Buck, A.; Maeder, U.; Einsele, H.; Knop, S. (2014). "The lymphoma-like polychemotherapy regimen Dexa-BEAM in advanced and extramedullary multiple myeloma". Ann Hematol. doi:10.1007/s00277-014-2023-2. PMID 24526137. Unknown parameter
|month=ignored (help) - ↑ Moreau, P. (2014). "The emerging role of carfilzomib combination therapy in the management of multiple myeloma". Expert Rev Hematol. doi:10.1586/17474086.2014.873699. PMID 24521249. Unknown parameter
|month=ignored (help) - ↑ Eda, H.; Santo, L.; Cirstea, DD.; Yee, A.; Scullen, TA.; Nemani, N.; Mishima, Y.; Waterman, PR.; Arastu-Kapur, S. (2014). "A novel Bruton's tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant anti-myeloma activity". Leukemia. doi:10.1038/leu.2014.69. PMID 24518207. Unknown parameter
|month=ignored (help)